Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05317416 · ClinicalTrials.gov registry record · Phase 3
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
A Phase 3 study of Multiple Myeloma, sponsored by Pfizer.
- Active
- Registry status
- Phase 3
- Development phase
- 811
- Enrollment target
- 20
- Study locations
NCT05317416 is a Phase 3 study of Multiple Myeloma that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 811 participants, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (49% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT05317416, a Phase 3 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 811 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately five years
Conditions Studied
Interventions
- DRUG Lenalidomide
- DRUG Elranatamab
Study Locations (20)
California
- Ronald Reagan UCLA Medical Center - Los Angeles
- UCLA Department of Medicine - Hematology/Oncology - Los Angeles
- UCLA Hematology/Oncology - Los Angeles
- UCLA Hematology/Oncology - Santa Monica - Los Angeles
- Santa Monica UCLA Medical Center & Orthopaedic Hospital - Santa Monica
Arizona
- Banner Gateway Medical Center - Gilbert
- Banner Gateway Medical Pavilion - Gilbert
- Banner MD Anderson Cancer Center - Gilbert
New York
- WMCHealth Advanced Physician Services - Hawthorne
- Westchester Medical Center - Valhalla
Ohio
- Cleveland Clinic - Cleveland
- OhioHealth Arthur G.H. Bing, MD, Cancer Center - Columbus
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Florida
- Miami Cancer Institute at Baptist Health, Inc. - Miami
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Illinois
- Loyola University Chicago - Maywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 811 participants |
| Start Date | 2022-03-25 |
| Est. Completion | 2029-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05317416
The ClinicalTrials.gov registry entry for NCT05317416 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 811 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (49% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Lenalidomide is the first listed.
NCT05317416 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Arizona, New York.
Frequently Asked Questions
What is clinical trial NCT05317416 about?
NCT05317416 is a clinical study titled "Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant". The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants...
What is the current status of trial NCT05317416?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 811 participants. The study started on 2022-03-25. Estimated completion is 2029-10-31.
What conditions does trial NCT05317416 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05317416?
The interventions under investigation include: Lenalidomide (DRUG), Elranatamab (DRUG).
Who is sponsoring clinical trial NCT05317416?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05317416 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.